Key points are not available for this paper at this time.
No takes yet. Share an insight, caveat, or question.
Nebivolol may confer broader cardiac and vascular protection than atenolol in metabolic syndrome rats; leaves open clinical translation in humans.
Toblli et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: